REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Disaggregation of Revenue [Line Items]
Total net revenues	$ 266,044	$ 211,371	$ 503,506	$ 408,493
Rare Disease total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	135,844	103,963	230,218	172,922
Cortrophin Gel
Disaggregation of Revenue [Line Items]
Total net revenues	117,126	81,647	192,245	134,497
ILUVIEN and YUTIQ
Disaggregation of Revenue [Line Items]
Total net revenues	18,718	22,316	37,973	38,425
Rare Disease and Brands total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	165,388	117,158	293,630	211,240
Brands
Disaggregation of Revenue [Line Items]
Total net revenues	11,813	13,195	24,141	38,318
Brand royalties and other revenues
Disaggregation of Revenue [Line Items]
Total net revenues	17,731	0	39,271	0
Generics and Other total net revenues
Disaggregation of Revenue [Line Items]
Total net revenues	100,656	94,213	209,876	197,253
Generic pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	99,051	90,297	204,453	188,975
Other generic revenues
Disaggregation of Revenue [Line Items]
Total net revenues	$ 1,605	$ 3,916	$ 5,423	$ 8,278